Navigation Links
Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
Date:7/25/2012

INDIANAPOLIS, July 25, 2012 /PRNewswire/ --

  • Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products.
  • Cymbalta revenue increased 22 percent due to continued strong growth in both the U.S. and international markets.
  • China and Japan delivered pharma revenue growth of 28 percent and 15 percent, respectively, providing counter-cyclical growth.
  • Elanco Animal Health continued its strong performance with revenue growth of 32 percent.
  • Second quarter earnings per share were $.83 (reported and non-GAAP).
  • 2012 earnings per share guidance range raised to $3.29 - $3.39 (reported), or $3.30 - $3.40 (non-GAAP).
  • Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2012.$ in millions, except per share data

    Second Quarter

    %20122011

    ChangeTotal Revenue – Reported

    $5,600.7$6,252.8

    (10)%Net Income – Reported

    923.61,197.3

    (23)%EPS – Reported

     

    0.831.07

    (22)%Net Income – non-GAAP

    923.61,315.9

    (30)%EPS – non-GAAP

    0.831.18

    (30)%Financial results for 2012 and 2011 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results exclude the items described in the reconciliation tables later in the release. The non-GAAP results are presented in order to provide additional insights into the underlying trends in the company's business. The company's 2012 financial guidance is also being provided on both a reported and a non-GAAP basis.
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
    2. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
    3. Lilly Diabetes Announces Once Upon A Time Contest Winner
    4. Lilly Statement on Affordable Care Act Ruling by Supreme Court
    5. Lilly Statement on PDUFA Vote by Senate
    6. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
    7. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
    8. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
    9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
    10. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    11. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
    (Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today reported its ... Cash and investments in marketable securities at ... million at March 31, 2014."The second half of 2014 will ... to significant milestones for a number of our late-stage clinical ... of Nektar. "The first of these is the potential US ...
    (Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
    Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
    (Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... offer health plans and employers effective options to ... narrow networks argue that they can enhance formulary ... administrative fees. Consultants report that nearly all PBMs ... to requests for proposals. The Aug. 12 ...
    (Date:8/1/2014)... 2014 Millions of women suffer with ... and in some cases the arms, causing an abnormal ... 17 million women in the U.S. alone are affected. ... the pain, embarrassment and discomfort caused by lipedema, it’s ... are unaware that this is a disease,” says Dr. David ...
    (Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 The ... important developments about chemical listings, appellate decisions, litigation ... that may affect compliance with California's Proposition 65. ... to the law, regulations, history and trends impacting ... the fourth installment of the series which adds ...
    (Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
    Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2
    ... is a sad day for the American labor movement and ... the bottom up, rather than the top down.SEIU,s press release ... It also is predictable that Hearing Officer Ray Marshall, former ... Stern to conduct the hearing would do the job he ...
    ... 22 Novo Nordisk, a global healthcare company focusing on ... "100 Best Companies to Work For" awards issue. This is ... award -- one of the most influential business scorecards in ... For" are historically good performers in the marketplace for not ...
    ... 22 Missouri Congressman Roy Blunt today reflected on the ... v. Wade by speaking with the Missouri-Illinois Right to Life ... in sending a letter to President Barack Obama urging him ... "The last few years are the first time since I,ve ...
    ... preventable blindnessOAK BROOK, Ill., Jan. 22 The ... http://www.newscom.com/cgi-bin/prnh/20081014/DC38855LOGO ) Who: Former President ... Lions Clubs International President Albert Brandel; ... Dedication of the "Gift of Sight" statue, ...
    ... 22 Griffin Hospital has been honored with a 10th year ... Griffin ranked 62 on the 2009 list released today. Griffin is ... ten years.Griffin was first invited to apply for selection to the ... since. FORTUNE has issued the list of "100 Best Companies to ...
    ... announced today that,the physicians of Midwest Pulmonary and ... , The physicians are Susan ... Plumb, M.D. All are board-certified in pulmonology,and critical care ... the treatment of sleep disorders. , ...
    Cached Medicine News:Health News:Statement by UHW on SEIU's Claims Regarding SEIU-Trusteeship Hearing Process Chaired by Ray Marshall 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 3Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 2Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 3Health News:Former President Jimmy Carter Dedicates 'Gift of Sight' Statue at Lions Club International Headquarters in Recognition of Lions' Blindness Prevention Efforts 2Health News:Griffin Honored with Tenth Year on FORTUNE Best Companies to Work for List 2Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2
    A sturdy, robust stool. Gas operated height adjustment for convenience....
    Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
    Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
    Anterior Chamber Needle, 27 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
    Medicine Products: